Latest market price
3.49
-0.06-1.69%
Earnings
Down 1.7% — Reported earnings — EPS in line, revenue beat by 4%.
High confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 88.75 | EPS (ttm) | 0.04 | Insider Own | 42.10% | Shs Outstand | 341.15M | Perf Week | -0.28% |
| Market Cap | 1.21B | Forward P/E | 10.11 | EPS next Y | 0.35 | Insider Trans | -1.62% | Shs Float | 280.94M | Perf Month | 8.23% |
| Enterprise Value | 1.45B | PEG | — | EPS next Q | 0.08 | Short Float | 1.31% | Perf Quarter | 6.29% | ||
| Income | 16.00M | P/S | 1.54 | EPS this Y | -15.83% | Short Ratio | 2.88 | Perf Half Y | 42.00% | ||
| Sales | 785.00M | P/B | 1.87 | EPS next Y | 15.79% | ROA | 0.69% | Short Interest | 3.67M | Perf YTD | 31.00% |
| Book/sh | 1.90 | P/C | 4.09 | EPS next 5Y | — | ROE | 2.61% | 52W High | 3.89 -10.28% | Perf Year | 3.20% |
| Cash/sh | 0.87 | P/FCF | 8.35 | EPS past 3/5Y | — | ROIC | 2.64% | 52W Low | 1.77 97.18% | Perf 3Y | -32.25% |
| Dividend Est. | — | EV/EBITDA | 8.47 | Sales past 3/5Y | 1.29% 7.66% | Gross Margin | 88.05% | Volatility | 3.58% 3.57% | Perf 5Y | -92.18% |
| Dividend TTM | — | EV/Sales | 1.85 | EPS Y/Y TTM | -63.86% | Oper. Margin | 10.25% | ATR (14) | 0.13 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 1.38 | Sales Y/Y TTM | -1.87% | Profit Margin | 2.07% | RSI (14) | 55.54 | Recom | 2.71 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.38 | EPS Q/Q | -11.11% | SMA20 | 2.60% | Beta | 1.64 | Target Price | 4.19 |
| Payout | 0.00% | Debt/Eq | 0.82 | Sales Q/Q | -1.48% | SMA50 | 3.41% | Rel Volume | 0.91 | Prev Close | 3.55 |
| Employees | 697 | LT Debt/Eq | 0.82 | Earnings | Nov 03 | SMA200 | 25.70% | Avg Volume | 1.28M | Price | 3.49 |
| IPO Date | Sep 23, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.40% 3.72% | Net Debt/EBITDA | 1.39 | Volume | 1,158,405 | Change | -1.69% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Reiterated | UBS | Neutral | $3.75 |
| Aug-07-26 | Reiterated | Goldman Sachs | Neutral | $3.50 → $4.00 |
| Aug-06-26 | Reiterated | Leerink Partners | $3.50 → $5.00 | |
| May-08-26 | Reiterated | Goldman Sachs | Neutral | $2.50 → $3.50 |
| Feb-27-26 | Downgrade | JP Morgan | Overweight → Neutral | |
| Feb-26-26 | Reiterated | Leerink Partners | $3.00 | |
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold | $2.75 |
| Dec-18-25 | Reiterated | Morgan Stanley | Equal Weight | $9.50 → $4.00 |
| Dec-08-25 | Initiated | Barclays | Underweight | $9.00 → $3.00 |
| Aug-11-25 | Reiterated | Deutsche Bank | Hold | $8.00 → $6.00 |
Latest News· Times ET
Nov-02-26
Nov-02-2612:58PM
Oct-31-26
Oct-31-2605:43AM
Oct-29-26
Oct-27-26
Oct-20-26
Oct-05-26
Sep-29-26
Sep-29-2606:04AM
Sep-14-26
Sep-04-26
Sep-03-26
Sep-03-2609:01AM
09:00AM
Aug-21-26
Aug-21-2607:07AM
Aug-13-26
Aug-12-26
Aug-12-2606:00AM
Company
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 785 | 797 | 792 | 750 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 93 | 58 | 48 | 67 | — | — | — | — | — | |
| Gross Profit | 691 | 739 | 744 | 683 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 434 | 446 | 485 | 467 | — | — | — | — | — | |
| Research and Development | 117 | 121 | 124 | 136 | — | — | — | — | — | |
| Other Operating Expense | 61 | 85 | 69 | 107 | — | — | — | — | — | |
| Operating Income | 82 | 87 | 66 | -27 | — | — | — | — | — | |
| Interest Expense | 41 | 43 | 53 | 57 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 12 | 19 | 28 | — | — | — | — | — | |
| Net Income Before Taxes | 41 | 57 | 31 | -56 | — | — | — | — | — | |
| Income Taxes | 25 | 26 | 15 | -47 | — | — | — | — | — | |
| Consolidated Net Income | 16 | 30 | 16 | -9 | — | — | — | — | — | |
| Net Income From Continuing Operations | 16 | 30 | 16 | -9 | — | — | — | — | — | |
| Net Income | 16 | 30 | 16 | -9 | — | — | — | — | — | |
| EPS (Recurring) | 0.05 | 0.09 | 0.04 | -0.02 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.05 | 0.09 | 0.04 | -0.02 | — | — | — | — | — | |
| EPS (Diluted) | 0.04 | 0.09 | 0.04 | -0.02 | — | — | — | — | — | |
| EBITDA | 171 | 184 | 154 | 109 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 87.25 | 31.77 | 111.24 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.51 | 1.21 | 2.27 | 3.66 | — | — | — | — | — | |
| Gross Margin | 88.03 | 92.72 | 93.94 | 91.07 | — | — | — | — | — | |
| Operating Margin | 10.45 | 10.92 | 8.33 | -3.60 | — | — | — | — | — | |
| Net Margin | 2.04 | 3.76 | 2.02 | -1.20 | — | — | — | — | — | |
| Shares Outstanding | 339 | 356 | 386 | 410 | — | — | — | — | — | |
| Market Capitalization | 1,183 | 965 | 1,795 | 2,747 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hirsch Douglas Joseph | Director | Oct 26 '26 | Option Exercise | 0.00 | 20,521 | 0 | 341,457 | Oct 26 |
| Barnes Wendy Lynn | Director, Officer | Oct 15 '26 | Option Exercise | 0.00 | 277,289 | 0 | 946,693 | Oct 15 |
| Fengler Justin | Officer | Oct 15 '26 | Option Exercise | 0.00 | 32,490 | 0 | 84,999 | Oct 15 |
| Chan Thomas (TC) | Chief Accounting Officer | Oct 15 '26 | Option Exercise | 0.00 | 5,793 | 0 | 20,371 | Oct 15 |
| Chan Thomas (TC) | Chief Accounting Officer | Sep 15 '26 | Option Exercise | 0.00 | 2,101 | 0 | 15,647 | Sep 15 |
| Fengler Justin | Officer | Sep 15 '26 | Option Exercise | 0.00 | 3,087 | 0 | 53,111 | Sep 15 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner | Aug 26 '26 | Sale | 3.51 | 856,867 | 3,004,332 | 0 | Aug 26 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner | Aug 25 '26 | Sale | 3.44 | 127,273 | 438,443 | 643,466 | Aug 26 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner | Aug 24 '26 | Sale | 3.46 | 143,594 | 497,123 | 706,649 | Aug 26 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner | Aug 21 '26 | Sale | 3.50 | 274,717 | 960,630 | 777,213 | Aug 21 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner | Aug 20 '26 | Sale | 3.52 | 447,259 | 1,574,576 | 913,592 | Aug 21 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner | Aug 19 '26 | Sale | 3.53 | 471,975 | 1,666,025 | 1,127,436 | Aug 21 |
| Chan Thomas (TC) | Chief Accounting Officer | Aug 15 '26 | Option Exercise | 0.00 | 10,115 | 0 | 15,857 | Aug 17 |
| Fengler Justin | Officer | Aug 15 '26 | Option Exercise | 0.00 | 48,532 | 0 | 61,988 | Aug 17 |
| McGinnis Christopher A | Officer | Jul 15 '26 | Option Exercise | 0.00 | 36,988 | 0 | 214,604 | Jul 16 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.